Zobrazeno 1 - 10
of 384
pro vyhledávání: ''
Autor:
Lene Hjerrild Iversen, Claus L. Andersen, Derrick Renner, Thomas Reinert, Ole Thorlacius-Ussing, Desamparados Roda, Tenna V Henriksen, Alexey Aleshin, Andrés Cervantes, Noelia Tarazona, Per Vadgaard Andersen, Shruti Sharma, Susana Roselló, J.A. Carbonell-Asins, Dina Hafez, Anders Husted Madsen, Uffe S. Løve, Kåre Andersson Gotschalck, Amanda Frydendahl, Marisol Huerta, F. Gimeno-Valiente, Himanshu Sethi
Publikováno v:
Henriksen, T V, Tarazona, N, Frydendahl, A, Reinert, T, Gimeno-Valiente, F, Carbonell-Asins, J A, Sharma, S, Renner, D, Hafez, D, Roda, D, Huerta, M, Roselló, S, Madsen, A H, Løve, U S, Andersen, P V, Thorlacius-Ussing, O, Iversen, L H, Gotschalck, K A, Sethi, H, Aleshin, A, Cervantes, A & Andersen, C L 2022, ' Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences ', Clinical Cancer Research, vol. 28, no. 3, pp. 507-517 . https://doi.org/10.1158/1078-0432.CCR-21-2404
Clinical cancer research : an official journal of the American Association for Cancer Research
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Clinical cancer research : an official journal of the American Association for Cancer Research
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the pred
Autor:
Cristiana Sessa, Monia Guidi, Laura Moser, Eleftherios P. Samartzis, Mariarosa Pascale, Ilaria Colombo, Tatiana Terrot, Milo Frattini, Simone Brandt, Anastasios Stathis, Sheila Gaggetta, Sofia Genta, Federica Martorana
Publikováno v:
Clinical Cancer Research. 27:5012-5019
Purpose: This phase I study evaluated safety, tolerability, pharmacokinetics, and preliminary activity of the PI3K/mTORC1/2 dual inhibitor gedatolisib combined with carboplatin and paclitaxel. Patients and Methods: Patients with advanced solid tumors
Autor:
Amy L. Cummings, Lyudmila Bazhenova, Edward B. Garon, Melissa Lynne Johnson, Alexander I. Spira, Joseph Leach, Mary J. Janatpour, Robert L. Coffman, Laura Q.M. Chow, Erick Gamelin, Albert Candia, Robert Janssen
Publikováno v:
Clinical Cancer Research. 27:4566-4573
Purpose: Although PD-(L)1 inhibitors have shown efficacy in advanced/metastatic non–small cell lung cancer (NSCLC), many patients do not respond to this treatment and more effective combinations with acceptable toxicities are needed. To assess the
Autor:
Mark Stroh, Melissa Lynne Johnson, Henry Castro, Jordi Rodon, Alexander I. Spira, Rachel E. Sanborn, Hirva Mamdani, Nehal Lakhani, Anthony B. El-Khoueiry, Song Wang, Navid Hafez, Valentina Boni, Alison L. Hannah, Javier Garcia-Corbacho
Publikováno v:
Clinical Cancer Research. 27:4521-4530
Purpose: PROCLAIM-CX-2029 is a phase I first-in-human study of CX-2029, a Probody–drug conjugate targeting CD71 (transferrin receptor 1) in adults with advanced solid tumors. Although the transferrin receptor is highly expressed across multiple tum
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Autor:
Rachel E. Sanborn, John E. Leonard, Crystal Mallow, Megan Ann Baumgart, Andreas Schröder, Nashat Y. Gabrail, Aaron S. Mansfield, Jonathan W. Goldman, Maurice Zauderer, Nagashree Seetharamu, JT Beck, Michael Shafique, Elizabeth E. Evans, Desa Rae Pastore, Ramaswamy Govindan, Ernest S. Smith, Kevin M. Chin, Yanyan Lou, Terrence L. Fisher, Vikas Mishra, Alexander I. Spira
Publikováno v:
Clinical Cancer Research. 27:3630-3640
Purpose: The CLASSICAL-Lung clinical trial tested the combination of pepinemab, an IgG4 humanized mAb targeting semaphorin 4D, with the PD-L1 inhibitor avelumab to assess the effects of coupling increased T-cell infiltration and reversal of immune su
Autor:
Jennifer Bordeaux, Dustin McCurry, Arivarasan Karunamurthy, Lisa H. Butterfield, Rogerio I. Neves, Anil Pahuja, Matthew P. Holtzman, Beiru Chen, Jehovana Orozco Bender, Ahmad A. Tarhini, Yan Zang, Ju Young Kim, John M. Kirkwood, Yan Lin, Cindy Sander, Joseph J. Skitzki, IlaSri B. Summit, Marc S. Ernstoff, Christian Laing, Joseph J. Drabick, Yana G. Najjar, Huang Lin, Jennifer Tsau, Ghanashyam Sarikonda, Igor Puzanov, Hassane M. Zarour, Zeni Alfonso, Amy Rose, James F. Pingpank, Diwakar Davar
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 15
Purpose:Neoadjuvant immunotherapy may improve the clinical outcome of regionally advanced operable melanoma and allows for rapid clinical and pathologic assessment of response. We examined neoadjuvant pembrolizumab and high-dose IFNα-2b (HDI) therap
Autor:
Hans-Peter Sinn, Christian Schem, Frederick Klauschen, Karsten Weber, Andreas Schneeweiss, Elmar Stickeler, Marion von Mackelenbergh, Dirk Michael Zahm, Sibylle Loibl, Bruno Valentin Sinn, Denise Treue, Claus Hanusch, Frederik Marmé, Clemens Becker, Michael Untch, Jenny Furlanetto, Carsten Denkert, Thomas Karn, Nicole Burchardi, Peter A. Fasching, Wolfgang D. Schmitt, Volkmar Müller
Publikováno v:
Clinical Cancer Research. 27:2584-2591
Purpose: We evaluated mRNA signatures to predict response to neoadjuvant PD-L1 inhibition in combination with chemotherapy in early triple-negative breast cancer. Experimental Design: Targeted mRNA sequencing of 2,559 transcripts was performed in for
Autor:
Vinay Raja, Micki Prager, Marc Hoffmann, Qamar J. Khan, Sheshadri Madhusudhana, Larry Beck, Lauren Nye, Rajvi H. Shah, Jaimie Heldstab, Dinesh Pal Mudaranthakam, Stephanie LaFaver, Roy A. Jensen, Roberto Rodríguez, Kelsey E. Larson, Gregory James Crane, Amanda L. Amin, Richard McKittrick, Venkatadri Beeki, Joshua M Staley, Lindsey Prochaska, Roberto Salgado, Maureen Sheehan, Rachel Yoder, Andrew K. Godwin, Manana Elia, Bruce F. Kimler, Larry Corum, Anuj Shrestha, Priyanka Sharma, Kathan Mehta, Christa R. Balanoff, Deepti Satelli, Jamie L. Wagner, Anne O'Dea, Milind A. Phadnis, Robert Pluenneke, Yen Y. Wang, Karissa Finke
Publikováno v:
Clin Cancer Res
Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisi
Autor:
Seth P. Lerner, Bruno R. Bastos, Dan Theodorescu, Jared S. Fowles, Thomas W. Flaig, Amir Goldkorn, Catherine M. Tangen, Daniel L. Gustafson, Rick Bangs, M. Scott Lucia, Gary R. MacVicar, David J. McConkey, Melissa Plets, Matthew I. Milowsky, Siamak Daneshmand, Ajjai Alva, Ian M. Thompson
Publikováno v:
Clin Cancer Res
Purpose: Dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC) and gemcitabine-cisplatin (GC) are accepted neoadjuvant regimens for muscle-invasive bladder cancer. The aim of this study was to validate the score from a coexpression extrap
Autor:
Rajiv M. Patel, Jae Eun Choi, Douglas R. Fullen, Nallasivam Palanisamy, Tasha M. Hughes, Bryan Johnson, Xiaoming Wang, Christopher K. Bichakjian, May P. Chan, Javed Siddiqui, Lili Zhao, Shannon Carskadon, Josh N. Vo, Steven M. Hrycaj, Kelly L. Harms, Scott A. Tomlins, Rahul Mannan, Scott A. McLean, Vincent T. Ma, Daniel R. Rhodes, Paul W. Harms
Publikováno v:
Clin Cancer Res
Purpose: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma that can be divided into two classes: virus-positive (VP) MCC, associated with oncogenic Merkel cell polyomavirus (MCPyV); and virus-negative (VN) MCC, associate